Literature DB >> 24637082

Visualization of liver uptake function using the uptake contrast-enhanced ratio in hepatobiliary phase imaging.

Shigeru Matsushima1, Yozo Sato2, Hidekazu Yamaura2, Mina Kato2, Yasutomi Kinosada3, Seiichi Era4, Kazuya Takahashi2, Yoshitaka Inaba2.   

Abstract

PURPOSE: To visualize liver uptake function using the uptake contrast-enhanced ratio in hepatobiliary phase (uptake CERH) magnetic resonance imaging.
MATERIALS AND METHODS: Thirty-seven patients with hepatocellular carcinoma (HCC) and 23 with metastatic liver cancer were evaluated. Hepatobiliary phase images were acquired 20min after an intravenous bolus injection of gadoxetic acid disodium. We assumed that the contrast-enhanced ratio in the hepatobiliary phase (CERH) in the spleen was similar to the contrast-enhanced ratio in the extracellular matrix (CEREM). The Uptake CERH value was defined as the percentage signal gain between the precontrast and hepatobiliary phase images (without CEREM). The Uptake CERH value measured the tumor-free liver parenchyma. The association of the uptake CERH value with the biochemical liver function test results, and hepatocellular density in the liver parenchyma was assessed. Correlations were examined using Pearson correlation coefficient and the Mann-Whitney test.
RESULTS: The uptake CERH value was correlated with albumin, bilirubin, indocyanine green retention rate at 15min, prothrombin activity(%), platelet count, and cellular density in the liver parenchyma (p<0.01).
CONCLUSIONS: Uptake CERH images are useful for visualizing liver uptake function.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Gadoxetic acid; Hepatobiliary phase; Indocyanine green retention rate; Liver; Uptake function

Mesh:

Substances:

Year:  2014        PMID: 24637082     DOI: 10.1016/j.mri.2014.02.017

Source DB:  PubMed          Journal:  Magn Reson Imaging        ISSN: 0730-725X            Impact factor:   2.546


  5 in total

1.  Evaluation of liver function in patients with chronic hepatitis B using Gd-EOB-DTPA-enhanced T1 mapping at different acquisition time points: a feasibility study.

Authors:  Jiamin Li; Boling Cao; Xinjun Bi; Weipeng Chen; Lanjing Wang; Zhongli Du; Xueqin Zhang; Xiangrong Yu
Journal:  Radiol Med       Date:  2021-06-08       Impact factor: 3.469

2.  Novel Imaging Diagnosis for Hepatocellular Carcinoma: Consensus from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014).

Authors:  Bang-Bin Chen; Takamichi Murakami; Tiffany Ting-Fang Shih; Michiie Sakamoto; Osamu Matsui; Byung-Ihn Choi; Myeong-Jin Kim; Jeong Min Lee; Ren-Jie Yang; Meng-Su Zeng; Ran-Chou Chen; Ja-Der Liang
Journal:  Liver Cancer       Date:  2015-10-15       Impact factor: 11.740

3.  Preoperative estimation of future remnant liver function following portal vein embolization using relative enhancement on gadoxetic acid disodium-enhanced magnetic resonance imaging.

Authors:  Yozo Sato; Shigeru Matsushima; Yoshitaka Inaba; Tsuyoshi Sano; Hidekazu Yamaura; Mina Kato; Yasuhiro Shimizu; Yoshiki Senda; Tsuneo Ishiguchi
Journal:  Korean J Radiol       Date:  2015-05-13       Impact factor: 3.500

4.  Correlation of liver enhancement in gadoxetic acid-enhanced MRI with liver functions: a multicenter-multivendor analysis of hepatocellular carcinoma patients from SORAMIC trial.

Authors:  Osman Öcal; Bora Peynircioglu; Christian Loewe; Otto van Delden; Vincent Vandecaveye; Bernhard Gebauer; Christoph J Zech; Christian Sengel; Irene Bargellini; Roberto Iezzi; Alberto Benito; Kerstin Schütte; Antonio Gasbarrini; Ricarda Seidensticker; Moritz Wildgruber; Maciej Pech; Peter Malfertheiner; Jens Ricke; Max Seidensticker
Journal:  Eur Radiol       Date:  2021-08-31       Impact factor: 5.315

5.  Evaluation of liver function using gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid enhanced magnetic resonance imaging based on a three-dimensional volumetric analysis system.

Authors:  Masashi Kudo; Naoto Gotohda; Motokazu Sugimoto; Tatsushi Kobayashi; Motohiro Kojima; Shinichiro Takahashi; Masaru Konishi; Ryuichi Hayashi
Journal:  Hepatol Int       Date:  2018-06-02       Impact factor: 6.047

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.